日达仙治疗重型肝炎临床观察  

Clinical Effect of Thymosin α_1 on Fulminant Hepatitis

作　　者：吴亮[1] 王颖[2] 张振刚[1] 田德英[1] 

机构地区：[1]华中科技大学同济医学院附属同济医院感染科,湖北武汉430030 [2]华中科技大学同济医学院附属同济医院消化科

出　　处：《中西医结合肝病杂志》2003年第6期335-336,共2页Chinese Journal of Integrated Traditional and Western Medicine on Liver Diseases

摘　　要：目的:研究免疫调节剂日达仙治疗重型肝炎的临床效果。方法:40例重型肝炎患者,18例给予日达仙治疗与常规治疗,22例给予常规对照治疗,观察临床指标变化及预后。结果:常规疗法结合日达仙治疗可有效降低患者TBil水平,提高PTA,增加血Cho含量,且明显提高患者存活率;同时两组存活患者住院费用相比无显著性差异。结论:日达仙可有效治疗慢性重型肝炎,改善患者预后。Objective: To investigate clinical effection of Thymosin α1 on fulminant hepatitis.Methods: 40 cases of fulminant hepatitis were divided into two groups, the first group with normal treatment, the second group with both normal treatment and Thymosin ai Results: Thymosin α1 could effectly depress the level of TBil, increase the level of PTA, CHO and survival rate, it was also found that there was not any significance difference between two groups.Conclusion: Thymosin α1 can effectly treat fulminant hepatitis and ameliorate the patient's prognosis.

关 键 词：日达仙 重型肝炎 临床观察 药物疗法 预后 细胞因子 肝功能 

分 类 号：R575.1[医药卫生—消化系统]